Please turn JavaScript on
Sleep Review icon

Sleep Review

Want to stay in touch with the latest updates from Sleep Review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.

Reading your RSS feed has never been easier!

Website title: Sleep Review – a MEDQOR brand

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  1.45 / day

Message History

The updated brpt.org features goal-based navigation and new interactive tools to help users easily access certification and recertification resources.

Key takeaways:

The Board of Registered Polysomnographic Technologists launched a redesigned website to improve the user experience for candidates, credential holders, and educators. New features i...

Read full story
The operator of an Oregon-based diagnostic testing group admits to overbilling federal and private insurers for sleep studies, resulting in an estimated loss of over $2.1 million.

Key takeaways:

Mehrdad Gerami, owner of Coastal Diagnostic Testing Group, pleaded guilty to conspiracy to commit healthcare fraud. The clinic billed for expensive in-o...

Read full story
The update translates recent evidence and expert consensus into practical guidance for managing restless legs syndrome. By Sree Roy

So much has changed in the management of restless legs syndrome (RLS) in just the last few years that the Restless Legs Syndrome (RLS) Foundation’s scientific and medical advisory board published an


Read full story
The proposed rule would move suvorexant, lemborexant, and daridorexant from Schedule IV to the less restrictive Schedule V under the Controlled Substances Act.

Key takeaways:

The US Drug Enforcement Administration proposes transferring three dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V. Evaluations by the Department of...

Read full story
The pharmaceutical company shared updates on its triple agonist retatrutide for obstructive sleep apnea and its acquisition of Centessa Pharmaceuticals.

Key takeaways:

Lilly’s triple agonist, retatrutide, demonstrated improvements in obstructive sleep apnea during clinical trials. The company finalized its acquisition of Centessa Pharmaceuticals...

Read full story